A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS012 monotherapy and combination with chemotherapy in patients with Advanced or Metastatic Solid Tumors.
Advanced or Metastatic Solid Tumors
DRUG: JS012|COMBINATION_PRODUCT: JS012 combine with chemotherapy
Incidence of DLT, The Incidence of dose-limiting toxicity（DLT）, Up to approximately 41 months from first patient in.|Incidence and severity of AE, The incidence and severity of adverse events (AE), Up to approximately 41 months from first patient in.|Incidence and severity of SAE, The incidence and severity of serious adverse events (SAE), Up to approximately 41 months from first patient in.|MTD, Determine maximum tolerated dose (MTD, if possible), Up to approximately 41 months from first patient in.|RP2D, Recommended phase II dose (RP2D) for JS012 monotherapy and combination therapy, Up to approximately 41 months from first patient in.
Drug concentrations, Drug concentrations in individual subjects at different time points after dosing, Up to approximately 41 months from first patient in.|Cmax, Peak concentration, Up to approximately 41 months from first patient in.|Tmax, Peak time, Up to approximately 41 months from first patient in.|Ctrough, Minimum concentration, Up to approximately 41 months from first patient in.|AUC0-T, Area under the curve from time zero to the time of the t, Up to approximately 41 months from first patient in.|AUC0-INF, Area under the curve from time zero to infinity, Up to approximately 41 months from first patient in.|t1/2, elimination half-life, Up to approximately 41 months from first patient in.|CL, clearance, Up to approximately 41 months from first patient in.|MRT, mean retention time, Up to approximately 41 months from first patient in.|Vss, steady-state apparent volume of distribution (Vss) (if applicable), Up to approximately 41 months from first patient in.|Css, Max, steady-state peak concentration Degree (Css, Max) (if applicable), Up to approximately 41 months from first patient in.|Css, min, Steady state minimum observed concentration (if applicable), Up to approximately 41 months from first patient in.|AUCss, steady-state area under curve (AUCss) (if applicable), Up to approximately 41 months from first patient in.|Rac, accumulation ratio (Rac) (if applicable), Up to approximately 41 months from first patient in.|Immunogenicity, Incidence of anti-drug antibody (ADA) and/or neutralizing antibody (Nab), titer of ADA positive samples, Up to approximately 41 months from first patient in.|ADCC, Antibody Dependent cell-mediated cytotoxicity (ADCC), Up to 21 days from pre-dose of JS012 administration in cycle 1 for each subject in the dose escalation and dose expansion phases|CDC, Complement dependent cytotoxicity(CDC), Up to 21 days from pre-dose of JS012 administration in cycle 1 for each subject in the dose escalation and dose expansion phases|ORR, Objective response rate (ORR) was assessed based on RECIST V1.1 criteria, Up to approximately 41 months from first patient in.|DOR, Duration of response (DOR) was assessed based on RECIST V1.1 criteria, Up to approximately 41 months from first patient in.|DCR, Disease control rate (DCR) was assessed based on RECIST V1.1 criteria, Up to approximately 41 months from first patient in.|TTR, Time to response (TTR) was assessed based on RECIST V1.1 criteria, Up to approximately 41 months from first patient in.|PFS, Progression-free survival (PFS) was assessed based on RECIST V1.1 criteria, Up to approximately 41 months from first patient in.|OS, Overall survival (OS), Up to approximately 41 months from first patient in.
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS012 monotherapy and combination with chemotherapy in patients with Advanced or Metastatic Solid Tumors.